Abstract
European Journal of ImmunologyVolume 52, Issue 8 Cover PictureFree Access Cover story: Eur. J. Immunol. 8'22 First published: 04 August 2022 https://doi.org/10.1002/eji.202270080AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Our cover depicts a comparison between uninfected (blue) and infected (red) human nasal mucosa. The SARS-CoV-2 has caused severe structural damage to the nasal mucosa. The image related to the article by Zhili Zhang et al., in which the authors report highly efficient SARS-CoV-2 viral infection and production in human nasal mucosa. Further examinations suggested that human NECRS nasal mucosa is particularly susceptible to SARS-CoV-2 infection, presumably due to an increase in ACE2-expressing cells and a deficiency in antiviral immune response. Therefore, patients with NECRS may be at a particularly high risk of viral infection and transmission and close monitoring should be considered. Volume52, Issue8August 2022 RelatedInformation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
